Results 1 to 10 of about 20,373 (181)

Roles of omalizumab in various allergic diseases

Allergology International, 2020
IgE and mast cells play a pivotal role in various allergic diseases, including asthma, allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody, has significantly improved control of these allergic diseases and ...
Yoshimichi Okayama, Hisako Matsumoto, Shunsuke Takahagi   +2 more
exaly   +3 more sources

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Therapeutic Advances in Respiratory Disease, 2018
Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that ...
Corrado Pelaia, Cecilia Calabrese, Rosa Terracciano   +2 more
exaly   +2 more sources

A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma [PDF]

Frontiers in Immunology
IntroductionPatients with severe asthma may benefit from targeted biological therapies. However, personalized therapy in children and adolescents with asthma, based on individual susceptibility to molecular mechanisms addressed by different biologicals ...
Boris Gole, Larisa Goričan, Gregor Jezernik, Mario Gorenjak, Anja Bizjak, Vojko Berce, Vojko Berce, Maja Skerbinjek Kavalar, Michael Kabesch, Erik Melén, Korneliusz Golebski, Cornelius M. van Drunen, Anke Hilse Maitland-van der Zee, Anke Hilse Maitland-van der Zee, Susanne Reinartz, Susanne J. H. Vijverberg, Susanne J. H. Vijverberg, Uroš Potočnik, Uroš Potočnik, Uroš Potočnik   +19 more
doaj   +2 more sources

Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study

Frontiers in Immunology, 2022
BackgroundAllergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose.
Rui Tang, Shubin Lei, Liping Zhu, Yuzhen Lv, Hong Li   +4 more
doaj   +1 more source

Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome

Dermatology Practical & Conceptual, 2022
Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic ...
Irene Russo, Sara Cazzolla, Francesca Pampaloni, Mauro Alaibac   +3 more
doaj   +1 more source

Omalizumab in Children [PDF]

Pediatric Drugs, 2014
Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating immunoglobulin E (IgE) and expression of IgE high-affinity receptors on mast cells and basophils, interrupting the subsequent allergic inflammatory cascade.
LICARI, AMELIA, MARSEGLIA, ALESSIA, CAIMMI, SILVIA MARIA, CASTAGNOLI, RICCARDO, FOIADELLI, THOMAS, MARSEGLIA, GIAN LUIGI, Barberi S   +6 more
openaire   +3 more sources

High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab

Clinical and Translational Allergy, 2021
Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended
Hanne Madsen, Charlotte G. Mortz, Carsten Bindslev‐Jensen, Mette Reilev, Jesper Hallas, Daniel P. Henriksen   +5 more
doaj   +1 more source

PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria

CPT: Pharmacometrics & Systems Pharmacology, 2023
The pharmacokinetic (PK) characteristics of omalizumab and its pharmacodynamic (PD) effect in patients has yet to be fully characterized in chronic spontaneous urticaria, which could elucidate its pathogenesis and treatment response.
Elise Oh, Russ Wada, Kha Le, Yanan Zheng, Jin Jin, Victor Poon, Kit Wong, Ryan Owen, Kenta Yoshida   +8 more
doaj   +1 more source

Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options [PDF]

, 2020
Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of
Abreu, C, Lopes, A, Lopes, C, Sokolova, A   +3 more
core   +1 more source

Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma

World Allergy Organization Journal, 2022
Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness
Nicola A. Hanania, MD, Robert Niven, MD, Pascal Chanez, MD, PhD, Deschildre Antoine, MD, PhD, Pascal Pfister, MD, Lorena Garcia Conde, MD, Xavier Jaumont, MD   +6 more
doaj   +1 more source